Dallas, Texas (PRWEB) October 02, 2012
The global market for nanoparticles in biotechnology, drug development and drug delivery was valued at $17.5 billion in 2011 and should reach nearly $21.6 billion in 2012. Total market value is expected to reach $53.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 19.9%. Drug delivery systems are expected to increase from $11.3 billion in 2012 to $30.9 billion in 2017, a CAGR of 22.2%. Drug development and formulation should total nearly $9.4 billion in 2012 and nearly $20.5 billion in 2017, a CAGR of 16.9%.
This study provides a comprehensive analysis of the market for nanoparticles in the life sciences on a global basis. Particular attention is given to drug development and formulation and the development of new drug delivery systems. Its aim is to provide a range of information, from detailed product analyses within health and wellness subsegments to overall industry trends in order to quantify and qualify the market for drug products for treating various disease conditions in both men and women. The applicability of specific types of nanoparticles for specific applications is discussed.
Forecasts and trends are developed from a cross-reference of data points gleaned from proprietary industry sources, company publications, industry benchmarking and other divergent data sources to arrive at a cogent and coordinated forecast.
REASONS FOR DOING THE STUDY
For companies with an effective strategy, market opportunities await. Importantly, the ability to develop an effective strategy begins with knowing where opportunity exists and ends with a plan to effectively execute in order to capture profit from opportunity.
The nanoparticle drug/delivery market presents an increasingly significant part of the overall pharmaceutical product market worldwide. This study investigates the specific classes of nanoparticles and the pharmaceutical products associated with them. Existing drug products and potential drugs in the pipelines of the major pharmaceutical players in this market are reviewed. Growing health concerns in developing countries are expected to continue to contribute substantially to market growth through the forecast period (2012 through 2017). This report analyzes emerging markets by technology category. Continued growth is expected in emerging geographies driven by the health awareness of the growing middle class in emerging countries such as India, China, Brazil and Russia.
This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and products, strategies for accessing emerging markets and awareness of specific disease prevalence and geographies thereof in order to allocate resources and make effective decisions.
SCOPE OF REPORT
Current and projected product forecasts during the forecast period of 2012 through 2017 are discussed. New product launches will be discussed. Revenue figure for 2011 are in an actual figures except where actual results have not been reported due to the timing of this report’s release.
The report includes analysis of leading and emerging drug products for each nanoparticle type. Profiles of manufacturers of leading products and their specific products are provided. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving nanoparticle-associated drugs.
Market figures are based on revenues at the manufacturer level and are projected at 2011 dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products and other factors affecting the market.
Included in this report are forecasts by product, product category and by company from 2010 through 2017. The study is arranged to offer an overview of existing nanoparticle technology and of drug markets; it is accompanied by nanoproduct, company, geography, and mechanism of action, with forecasts broken down and covered by geographic region or country.
Patent and clinical trial information is reviewed for various candidate nanodrugs. The status of approvals of drugs in each segment by the FDA and regulatory agencies in other countries is reviewed.
Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
26 Company Profiles Covered:
1. Abraxis Biosciences, Inc
2. Abraxis Pharmaceutical Products
3. Access Pharma, Inc.
4. Alnylam Pharmaceuticals, Inc.
5. Amag Pharmaceuticals, Inc.
6. Aphios Corporation
7. Asklepios Biopharmaceutical, Inc.
8. Astrazeneca Pharmaceuticals, Plc
9. Bind Biosciences, Inc
10. Cerulean Pharma Inc.
12. Debiotech, S.A.
13. Elan Pharmaceuticals, Inc.
14. Browse more company profiles @ http://www.reportsnreports.com/reports/195543-nanoparticles-in-biotechnology-drug-development-and-drug-delivery.html
Browse more reports on Biotechnology Market
Contact firstname.lastname@example.org for further information.
ReportsnReports.com is an online market research reports library of 200,000+ in-depth studies of 5000+ micro markets. We provide 24/7 online and offline support service to our customers.